Business Context and Reporting Period
This Form 8-K, filed on March 14, 2024, reports the results of a special meeting of stockholders held by Graphite Bio, Inc. (the "Company") regarding its proposed merger with LENZ Therapeutics, Inc. ("LENZ"). The filing details the approval of the Merger Agreement entered into on November 14, 2023, under which Graphite will acquire LENZ, with LENZ continuing as a wholly owned subsidiary. The Company is an emerging growth company listed on the NASDAQ Global Market under the symbol "GRPH."
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
The primary material event is the successful approval of the merger and related corporate actions by Graphite stockholders. A quorum was established with 48,498,051 shares represented out of 58,230,156 outstanding shares. All four main proposals were approved:
- Proposal 1 (Merger and PIPE): Approved the issuance of shares to LENZ stockholders and PIPE investors, representing more than 20% of pre-merger outstanding shares.
- For: 40,937,960
- Against: 37,089
- Abstain: 1,898
- Broker Non-Votes: 7,521,104
- Proposal 2 (Reverse Split and Name Change): Approved an amendment to the certificate of incorporation to effect a reverse stock split (ratio between 1:6 and 1:12) and change the Company name to "LENZ Therapeutics, Inc."
- For: 48,324,362
- Against: 169,990
- Abstain: 3,699
- Broker Non-Votes: 0
- Proposal 3 (2024 Equity Incentive Plan): Approved the combined company's 2024 Equity Incentive Plan.
- For: 36,564,189
- Against: 4,398,998
- Abstain: 13,760
- Broker Non-Votes: 7,521,104
- Proposal 4 (2024 Employee Stock Purchase Plan): Approved the combined company's 2024 Employee Stock Purchase Plan.
- For: 37,291,832
- Against: 3,672,224
- Abstain: 12,891
- Broker Non-Votes: 7,521,104
- Proposal 5 (Adjournment): Not presented to stockholders as sufficient votes were obtained for Proposals 1 and 2.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the structure, timing, and completion of the merger, the concurrent private financing, and the future operations of the combined company. Management expects the combined entity to list on Nasdaq and outlines expectations for cash position, runway, and clinical development timelines. However, the filing explicitly disclaims any obligation to update these statements. Key risks include the failure to satisfy conditions to closing, uncertainties in the private financing, and general risks associated with clinical drug development and commercialization.
Investor Verification Checklist
- Verify the final reverse stock split ratio (between 1:6 and 1:12) to be determined by the boards prior to the effective time.
- Confirm the closing date of the Merger and the concurrent private financing (PIPE) to assess the expected cash runway.
- Review the definitive proxy statement/prospectus filed on February 13, 2024, for detailed terms of the merger and equity issuance.
- Monitor the transition of the trading symbol from "GRPH" to the new ticker for "LENZ Therapeutics, Inc."
- Check for any subsequent filings regarding the satisfaction of closing conditions or delays in the transaction.